Overview

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Asparaginase
BB 1101
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin
Mesna
Methotrexate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Pegaspargase
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rituximab
Vincristine
Criteria
Inclusion Criteria:

1. Newly diagnosed, previously untreated Acute Lymphoblastic Leukemia (ALL) or
lymphoblastic lymphoma, or having achieved Complete Remission (CR) with one course of
induction chemotherapy.

2. Failure to one induction course of chemotherapy are eligible, but these patients will
be analyzed separately.

3. All ages are eligible.

4. Zubrod performance less than or equal to 3

5. Adequate liver function (bilirubin renal function (creatinine
6. Adequate cardiac function as assessed by history and physical examination.

7. No active co-existing malignancy with life expectancy less than 12 months due to that
malignancy.

Exclusion Criteria:

1) N/A